MW101: Eli Lilly-Backed RNAi Obesity Bet Carries Preclinical-Only Evidence Into a GLP-1-Dominated Market

Moonwalk Secures $70M for RNAi Obesity Candidate MW101

Moonwalk Biosciences, an Eli Lilly-backed company, has successfully closed a $70 million Series B funding round. This capital infusion is designated to propel its lead obesity candidate, MW101, an RNAi-based treatment, into first-in-human clinical trials by late 2027. Preclinical studies have shown promising results for MW101, demonstrating significant weight loss and fat reduction in mice while crucially preserving muscle mass. This differentiated profile aims to address a key challenge in the rapidly expanding metabolic market, currently dominated by GLP-1 agonists from pharmaceutical giants like Eli Lilly and Novo Nordisk, by offering a potential treatment without the common side effects of gastric upset and muscle loss.

• Moonwalk Biosciences secured $70 million in Series B financing, led by Alpha Wave Ventures and YK Bioventures, with notable participation from Eli Lilly, Gaorong Ventures, ARCH Venture Partners, Khosla Ventures, and Future Ventures. This substantial investment is critical for advancing the company's lead obesity candidate, MW101, towards its planned first-in-human studies.
• MW101 employs a novel small interfering RNA (siRNA) approach to specifically target adipose tissue, which is responsible for fat storage and is believed to be central to the underlying causes of obesity. This mechanism distinguishes it from existing GLP-1 receptor agonists by aiming for fat reduction and weight loss while uniquely preserving lean muscle mass and not impacting food intake, potentially offering a more favorable patient profile.
• The Series B funding will directly support the initiation of MW101's first-in-human trials in late 2027, marking a significant step towards clinical validation. Moonwalk's broader pipeline, currently in preclinical stages, is driven by an AI platform that integrates various omics data to identify and develop adipose-targeted siRNA therapies, positioning the company to potentially redefine obesity treatment with durable efficacy and infrequent dosing.

Addressing Unmet Needs in the Evolving Obesity Treatment Landscape

Current obesity treatment approaches — spanning pharmacotherapy, surgical intervention, and lifestyle modification — each carry distinct limitations that complicate long-term disease management. The interplay of tolerability concerns, nutritional risks, treatment sustainability, and post-discontinuation weight regain collectively represents a substantial unmet need in clinical practice.

• Gastrointestinal tolerability of GLP-1 receptor agonists: GLP-1 RAs, including semaglutide and tirzepatide, are associated with frequent gastrointestinal adverse events — nausea, vomiting, diarrhea, and constipation — particularly during dose escalation. In a meta-analysis of semaglutide in non-diabetic adults, treatment discontinuation due to adverse events was significantly higher in the semaglutide group (RR 2.62, 95% CI: 1.70–4.03; P = .001), underscoring the impact of tolerability on adherence.

• Loss of lean mass with pharmacotherapy: Weight loss induced by GLP-1 RAs is accompanied by reductions in lean mass, including skeletal muscle. In a murine model of diet-induced obesity, semaglutide reduced muscle mass and strength to a similar extent as caloric restriction, raising concerns about functional consequences — particularly in elderly patients, where use "may be harmful" given the absence of long-term data.

• Weight regain following treatment discontinuation: Discontinuation of semaglutide leads to loss of treatment effects, with lean and fat mass rebounding to baseline levels. Observational evidence suggests that weight regain following pharmacotherapy discontinuation can be composed primarily of fat, and multiple cycles of weight loss and regain "may actually increase obesity in individuals." The high cost and limited availability of new weight loss drugs contribute to large rates of discontinuation.

• Nutritional deficiencies after bariatric surgery: Bariatric surgery carries a long-term risk of nutritional deficiencies, including iron, vitamin B12, folate, copper, and vitamins B1, A, K, D, and E. Data from the Swedish Obese Subjects study demonstrated that the incidence of anaemia was substantially higher in the gastric bypass group (64 cases per 1000 person-years) compared with controls (13 cases per 1000 person-years), with a hazard ratio of 5.05 (95% CI: 3.94–6.48; p<0.0001) over a median follow-up of 10 years.

• Inadequate integration of lifestyle interventions: The optimal timing, frequency, and content of lifestyle interventions alongside obesity management medications remain unclear. While protein intake and resistance training are effective in mitigating muscle and bone loss during pharmacotherapy, barriers to implementation and long-term adherence persist. Pre-treatment lifestyle programs may also limit access and reinforce stigma, representing a structural challenge in equitable obesity care.

Moonwalk's RNAi Approach: A Novel Target for Adipose Tissue

Recent research has expanded the therapeutic landscape for obesity well beyond conventional approaches, with several mechanistically distinct targets now demonstrating clinical and preclinical promise. Incretin-based multi-agonist strategies have advanced substantially: tirzepatide (GLP-1/GIP dual agonist), CagriSema (GLP-1/amylin dual agonist), and retatrutide (GLP-1/GIP/glucagon triple agonist) have achieved unprecedented levels of weight loss and glycemic improvement, with retatrutide achieving up to 24.2% mean weight loss after 48 weeks in individuals with obesity. Further, a unimolecular FGF21/GLP-1/GIP triagonist has been engineered to achieve near normalization of body weight in diet-induced obesity (DIO) mice, demonstrating significant reductions in body fat, improved glucose tolerance, and extended duration of action — positioning it as a first-in-class candidate for next-generation metabolic disease therapy. Cagrilintide, a long-acting amylin and calcitonin receptor agonist, engages homoeostatic and hedonic brain regions to induce satiety, and its combination with semaglutide has shown promising weight loss in clinical trials through additive appetite-reducing mechanisms.

Beyond incretin pharmacology, adipose tissue biology has emerged as a distinct and active area of investigation. Suppression of α/β-domain hydrolase-6 (ABHD6), a monoacylglycerol hydrolase, has been shown to induce white adipose browning, increase energy expenditure, and enhance cold-induced thermogenesis in high-fat-diet-fed knockout mice, with the mechanism involving PPARα and PPARγ activation via lipolysis-derived 1-MAG signaling. Natural bioactive compounds capable of promoting beige adipocyte recruitment and activation have similarly attracted attention as potential browning agents, given that browned white adipose tissue (WAT) resembles brown adipose tissue (BAT) morphologically and metabolically and can produce heat to counter obesity and its metabolic complications.

Gut microbiota-targeted strategies represent a third emerging axis. Microbiome-targeted interventions — including probiotics, prebiotics, synbiotics, and fecal microbiota transplantation — have demonstrated significant reductions in body weight, BMI, body fat percentage, lipid profiles, and inflammatory markers such as IL-6, IL-8, and C-reactive protein in overweight and obese adults. Red ginseng (RGS) has been shown to enrich Akkermansia muciniphila, whose derived protein Amuc_1631 promotes GDF15 secretion, activating the brainstem GDF15-GFRAL pathway to suppress food intake; depletion of A. muciniphila abrogated RGS-mediated weight loss and appetite suppression in diet-induced obese mice. Collectively, these converging lines of research reflect a paradigm shift toward precision metabolic medicine, with multi-target pharmacology and microbiome-informed approaches offering broad clinical utility beyond glucose lowering.

Beyond GLP-1s: Emerging Mechanisms of Action in Obesity

The obesity pharmacology landscape has undergone a significant mechanistic expansion over the past three years, moving well beyond single-receptor GLP-1 engagement toward multi-hormonal and centrally acting strategies. Emerging agents now target combinations of gastro-entero-pancreatic hormone receptors — including GIP, glucagon, amylin, and peptide YY — to amplify energy expenditure, reduce food intake, and improve metabolic plasticity through synergistic mechanisms.

• Dual GLP-1/GIP receptor modulation: Both GIP receptor agonism and antagonism, in combination with GLP-1 receptor agonism, have shown promise. Maridebart cafraglutide combines GLP-1R agonism with GIPR antagonism, while tirzepatide exemplifies dual GLP-1/GIP co-agonism. These approaches leverage complementary incretin pathways to enhance glycemic control and weight reduction beyond what single GLP-1R agonism achieves.

• Glucagon co-agonism: Agents such as survodutide and mazdutide co-activate glucagon receptors alongside GLP-1 receptors, demonstrating significant weight loss and improved glycemic control. Glucagon receptor engagement is understood to amplify energy expenditure, adding a thermogenic dimension to the incretin-based mechanism.

• Triple receptor agonism (GIP/GLP-1/glucagon): Retatrutide targets GIP, GLP-1, and glucagon receptors simultaneously. In phase 2 clinical trials, the 12 mg dosage showed the most significant reductions in body weight, body mass index, and waist circumference, with a higher proportion of patients achieving weight losses of ≥5%, 10%, 15%, and 20%. Phase 3 TRIUMPH studies are ongoing to evaluate long-term safety and efficacy.

• Amylin receptor agonism: Amylin, a neuroendocrine hormone co-released with insulin, controls hunger, gastric motility, glucagon secretion, and energy metabolism via amylin receptor (AMYR) subtypes — specifically the calcitonin receptor (CTR) and receptor activity-modifying proteins (RAMPs). Peptide-based amylin receptor agonists (AMYRAs) including pramlintide, cagrilintide, KBP-series DACRAs, ZP8396, and amycretin have demonstrated enhanced pharmacokinetics and synergy with GLP-1 receptor agonists. Cagrilintide achieved weight loss exceeding 10% of total body weight in early clinical trials. CagriSema (cagrilintide + semaglutide) and amycretin represent combination strategies that enhance satiety and glycemic outcomes through complementary amylin and GLP-1 mechanisms.

• Oral small-molecule GLP-1 receptor agonists: Danuglipron and orforglipron are orally active small-molecule GLP-1 receptor agonists that are resistant to enzymatic degradation. Orforglipron is described as the first non-peptide oral GLP-1RA. This class represents a major advance in patient-friendly drug delivery, distinct from the injectable peptide-based agents that have dominated the field.

• Neuropeptide Y receptor type 2 (NPY2R) agonism: BI 1820237, a peptidic NPY2R agonist, has entered first-in-human phase 1 investigation. Neuropeptide Y and peptide YY bind G-protein-coupled Y receptors and represent targets for modulating body weight. In combination with low-dose liraglutide, BI 1820237 exhibited additive effects on gastric emptying, though transient nausea and vomiting were observed at higher doses.

• Melanocortin-4 receptor (MC4R) pathway modulation: MC4R is a G protein-coupled receptor that controls systemic energy balance by regulating food intake and energy expenditure via cAMP signaling. CRTC1 deficiency in Mc4r-expressing cells in murine models produced modest obesity, glucose intolerance, insulin resistance, decreased energy expenditure, and impaired thermogenic programs in brown adipose tissue and skeletal muscle, reinforcing the pathway's relevance as a mechanistic target. Additionally, a high-throughput peptide display platform identified a novel D5H mutant of β-melanocyte-stimulating hormone (β-MSH) with enhanced MC4R activation, offering insights for therapeutic peptide design in this pathway.

RNAi's Bold Bid to Redefine Obesity Treatment

The recent $70 million Series B funding for Moonwalk Biosciences, an Eli Lilly-backed venture, signals a pivotal moment for the future of obesity treatment. This substantial investment is earmarked to advance MW101, an RNAi-based therapy, into its first human clinical trials by late 2027. This move is not merely about a new drug; it represents a strategic bet on a novel therapeutic modality to address one of the most pressing global health challenges.

The current obesity market is largely dominated by GLP-1 receptor agonists, which have demonstrated significant weight loss efficacy. However, studies indicate these therapies are frequently associated with gastrointestinal side effects such as nausea, vomiting, and delayed gastric emptying, alongside concerns regarding muscle mass preservation. MW101's preclinical data, showcasing significant weight and fat reduction while crucially preserving muscle mass and avoiding these common gastric issues, positions it as a potentially differentiated alternative.

This development carries several strategic implications:

• It underscores a growing industry confidence in RNAi technology as a powerful tool for chronic metabolic diseases, moving beyond its established role in infectious disease and rare genetic disorders.

• The entry of a well-funded, Eli Lilly-backed RNAi candidate could intensify competitive pressure on existing GLP-1 market leaders, potentially driving further innovation in tolerability and body composition outcomes.

• It represents a strategic diversification for Eli Lilly, allowing them to explore a distinct mechanism of action in the obesity space, complementing their existing GLP-1 portfolio.

However, the path forward is not without its challenges. Translating preclinical promise into human success for RNAi therapeutics, particularly for a chronic condition like obesity, involves navigating complex hurdles related to drug delivery systems. Research highlights the ongoing need to optimize lipid nanoparticle (LNP) formulations for efficient and stable intracellular delivery. Furthermore, the long-term safety and potential for off-target effects or immunogenicity with sustained gene silencing in humans will require rigorous evaluation. Despite these considerations, the successful funding round for MW101 marks a bold step towards a potentially transformative, gene-silencing approach to obesity management, offering a glimpse into a future where treatment options are more diverse and tailored to patient needs.